Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Daiichi Sankyo Co Ltd Result of Phase III Clinical Trial for Antiplatelet Drug
Daiichi Sankyo Co Ltd announced the result of the domestic phase III clinical trial for its antiplatelet Drug. The phase III clinical trial confirmed the dose-response and the safety of the drug.
Latest Developments for Daiichi Sankyo Co Ltd
- Daiichi Sankyo Co Ltd to Apply for Delisting from Nagoya Stock Exchange
- Daiichi Sankyo Co Ltd And Ranbaxy Laboratories Ltd Announce Intention To Integrate Business Operations In Thailand
- Daiichi Sankyo Co Ltd and ArQule, Inc. Announces Top-Line Results Of Phase 2 Trial With Tivantinib in Colorectal Cancer
- Arqule Inc And Daiichi Sankyo Co Ltd Announces Discontinuation Of Phase 3 MARQUEE Clinical Trial In Non-Small Cell Lung Cancer
Latest Key Developments in Pharmaceuticals
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb From Warburg Pincus LLC-Reuters
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb-Reuters
- Astec LifeSciences Ltd Recommends Dividend; Announces Appointment Of Statutory Auditors
- J B Chemicals and Pharmaceuticals Ltd Recommends Dividend
- Share this
- Link this
- Digg this
Follow Reuters